Camstent Ltd., a Colworth, Bedforshire, UK-based company developing proprietary bacteria-phobic polymers to apply to medical devices, raised £600k in funding.
The company intends to use the funds to:
– continue clinical evaluations,
– pursue regulatory milestones,
– make key appointments to the executive team,
– double its manufacturing and lab space,
– increase production of its unique polymer coated Foley catheter, and
– apply its patented coating to other in-body medical devices to develop new products.
Led by Dr Dave Hampton (CTO & Co Founder) and Dr Paul Harper (Chief Executive Officer), Camstent addresses the problem of hospital-acquired infections that affect 1 in 25 patients via bacteria-phobic polymers, which, first discovered at the University of Nottingham in 2012, have been formulated as a coating for catheters and other silicon/silastic medical devices.
Its CE marked Coated Foley catheter, already approved for sale in the UK and EU and being used in hospitals in the UK, is intended for the drainage of urine from the urinary bladder.